CA2229662A1 - Endometrial ablation using photodynamic therapy with green porphyrins - Google Patents

Endometrial ablation using photodynamic therapy with green porphyrins Download PDF

Info

Publication number
CA2229662A1
CA2229662A1 CA002229662A CA2229662A CA2229662A1 CA 2229662 A1 CA2229662 A1 CA 2229662A1 CA 002229662 A CA002229662 A CA 002229662A CA 2229662 A CA2229662 A CA 2229662A CA 2229662 A1 CA2229662 A1 CA 2229662A1
Authority
CA
Canada
Prior art keywords
endometrium
green porphyrin
bpd
green
endometrial
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002229662A
Other languages
English (en)
French (fr)
Inventor
Yona Tadir
Michael W. Berns
Bruce J. Tromberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2229662A1 publication Critical patent/CA2229662A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CA002229662A 1995-08-14 1996-08-06 Endometrial ablation using photodynamic therapy with green porphyrins Abandoned CA2229662A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US227695P 1995-08-14 1995-08-14
US60/002,276 1995-08-14

Publications (1)

Publication Number Publication Date
CA2229662A1 true CA2229662A1 (en) 1997-02-27

Family

ID=21700029

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002229662A Abandoned CA2229662A1 (en) 1995-08-14 1996-08-06 Endometrial ablation using photodynamic therapy with green porphyrins

Country Status (7)

Country Link
EP (1) EP0844876A4 (es)
JP (1) JP2000502044A (es)
AR (1) AR004181A1 (es)
AU (1) AU6692396A (es)
CA (1) CA2229662A1 (es)
WO (1) WO1997006797A1 (es)
ZA (1) ZA966833B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2821831T3 (es) * 2009-06-11 2021-04-27 Photocure Asa Composiciones y productos farmacéuticos semisólidos que comprenden ésteres de ácido 5-aminolevulínico
RU2714599C1 (ru) * 2018-12-26 2020-02-18 Министерство науки и высшего образования Российской Федерации Федеральное государственное бюджетное учреждение здравоохранения Центральная клиническая больница Российской академии наук (ЦКБ РАН) Способ лечения бесплодия у пациенток с хроническим эндометритом

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5283255A (en) * 1987-01-20 1994-02-01 The University Of British Columbia Wavelength-specific cytotoxic agents
US5422093A (en) * 1989-07-28 1995-06-06 Queen's University Photochemotherapeutic method using 5-aminolevulinic acid and precursors thereof
US5234940A (en) * 1989-07-28 1993-08-10 Queen's University Photochemotherapeutic method using 5-aminolevulinic acid and precursors thereof
US5330741A (en) * 1992-02-24 1994-07-19 The Regents Of The University Of California Long-wavelength water soluble chlorin photosensitizers useful for photodynamic therapy and diagnosis of tumors

Also Published As

Publication number Publication date
JP2000502044A (ja) 2000-02-22
WO1997006797A1 (en) 1997-02-27
ZA966833B (en) 1997-02-27
EP0844876A4 (en) 1999-12-01
AR004181A1 (es) 1998-11-04
EP0844876A1 (en) 1998-06-03
AU6692396A (en) 1997-03-12

Similar Documents

Publication Publication Date Title
Loh et al. Photodynamic therapy of the normal rat stomach: a comparative study between di-sulphonated aluminium phthalocyanine and 5-aminolaevulinic acid
Benson Jr et al. Treatment of transitional cell carcinoma of the bladder with hematoporphyrin derivative phototherapy
Fingar et al. Analysis of acute vascular damage after photodynamic therapy using benzoporphyrin derivative (BPD)
Dougherty Photodynamic therapy (PDT) of malignant tumors
US6058937A (en) Photodynamic Therapy of highly vascularized tissue
US5422093A (en) Photochemotherapeutic method using 5-aminolevulinic acid and precursors thereof
US5234940A (en) Photochemotherapeutic method using 5-aminolevulinic acid and precursors thereof
Herrera‐Ornelas et al. Photodynamic therapy in patients with colorectal cancer
Regula et al. Photodynamic therapy using 5-aminolaevulinic acid for experimental pancreatic cancer–prolonged animal survival
Grant et al. Photodynamic therapy of normal rat arteries after photosensitisation using disulphonated aluminium phthalocyanine and 5-aminolaevulinic acid
Kim et al. Photodynamic therapy of pigmented choroidal melanomas of greater than 3-mm thickness
Grant et al. The effect of photodynamic therapy on the mechanical integrity of normal rabbit carotid arteries
Yang et al. Evidence of lasting functional destruction of the rat en dometrium after 5-aminolevulinic acid—induced photodynamic ablation: Prevention of implantation
Steiner et al. Photosensitization of the rat endometrium following 5‐aminolevulinic acid induced photodynamic therapy
Yang et al. Intrauterine 5‐aminolevulinic acid induces selective fluorescence and photodynamic ablation of the rat endometrium
Loh et al. Mucosal ablation using photodynamic therapy for the treatment of dysplasia: an experimental study in the normal rat stomach.
Yang et al. Fluorescence and photosensitization of experimental endometriosis in the rat after systemic 5-aminolevulinic acid administration: a potential new approach to the diagnosis and treatment of endometriosis
Barr et al. The significance of the nature of the photosensitizer for photodynamic therapy: quantitative and biological studies in the colon
Van Hillegersberg et al. Interstitial photodynamic therapy in a rat liver metastasis model
Hugh-Jones et al. Laser photodynamic therapy for inoperable bronchogenic squamous carcinoma
Wyss et al. Photomedicine of the endometrium: experimental concepts
CA2229662A1 (en) Endometrial ablation using photodynamic therapy with green porphyrins
Steiner et al. Rat reproductive performance following photodynamic therapy with topically administered Photofrin
Chapman et al. Effect of administration route and estrogen manipulation on endometrial uptake of Photofrin porfimer sodium
Fehr et al. Structural and functional effects of endometrial photodynamic therapy in a rat model

Legal Events

Date Code Title Description
FZDE Dead